141790-23-0
Chemical Structure
Fozivudine tidoxil
Synonym(s): BM-211290
- CAS No.: 141790-23-0
- Formula:C35H64N5O8PS
- Molecular Weight:745.95
IUPAC Name: ((2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl (2-(decyloxy)-3-(dodecylthio)propyl) hydrogen phosphate
InChIKey: IBHARWXWOCPXCR-WELGVCPWSA-N
SMILES: O=C(NC1=O)N(C=C1C)[C@](C[C@@H]2N=[N+]=[N-])([H])O[C@@H]2CO[P](OCC(OCCCCCCCCCC)CSCCCCCCCCCCCC)(O)=O
Biological Activity: Fozivudine tidoxil (BM-211290) is an orally active thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity. Fozivudine tidoxil, a member of the NRTI family of agent, is incorporated into the newly synthesized strand of DNA during intracellular viral replication and irreversibly binds viral RT which disrupts viral reverse-transcription[1][2]. Fozivudine tidoxil is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fozivudine tidoxil | Fozivudine tidoxil (BM-211290) is an orally active thioether lipid-zidovudine (ZDV) conjugate with anti-HIV activity. Fozivudine tidoxil, a member of the NRTI family of agent, is incorporated into the newly synthesized strand of DNA during intracellular viral replication and irreversibly binds viral RT which disrupts viral reverse-transcription. Fozivudine tidoxil is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Michelle M Miller, et al. Administration of Fozivudine Tidoxil as a Single-Agent Therapeutic During Acute Feline Immunodeficiency Virus Infection Does Not Alter Chronic Infection. Viruses. 2012 Jun;4(6):954-62. [Content Brief]
- [2]. P M Girard, et al. Phase II Placebo-Controlled Trial of Fozivudine Tidoxil for HIV Infection: Pharmacokinetics, Tolerability, and Efficacy. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):227-35. [Content Brief]
Keywords
